IONTAS collaboration with F-star enters oncology Phase 1 clinical trial

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, has announced that F-star Therapeutics, Inc. has dosed the first patients in a Phase 1 clinical trial, with FS222, a CD137/PD-L1 bispecific antibody.

IONTAS applied its proprietary technology to generate a component utilized within FS222, which was subsequently licensed to F-star. The initiation of this trial adds to the growing portfolio of antibodies generated by IONTAS that are entering clinical trials.

António Parada, CEO at IONTAS, commented: “We are delighted with the progress of this molecule, the platform offered by F-star taps into the growing number of bispecific antibodies entering the clinic and we are proud to be part of this movement. We wish F-star every success with the clinical trial and hope this can be the foundation of an effective cancer treatment.”

For more of the latest science news, straight to your inbox, become a member of SelectScience for free today>>